$MRNA

Stéphane Bancel

Moderna

CEO • Since 2011 • Health Care

Also profiled in: S&P 500

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

75/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: −$4.1B → −$2.1B (+49.1% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): −$3.6B → −$2.8B (+20.8% YoY) — fiscal 2025 vs fiscal 2024

How this score works · Nasdaq-100 reputation leaderboard

Overview

Stéphane Bancel is the ceo of Moderna since 2011. Moderna is a Health Care company, and one of the 100 companies in the Nasdaq-100 — every one of which is profiled on this site.

Leadership

Stéphane holds the chief executive role at Moderna with the title CEO — in post since 2011. This page is the concise leadership record for Moderna in the Nasdaq-100 CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $MRNA
CEO since: 2011
Index: Nasdaq-100 (#62 of 100)